Abemaciclib Market, By Indication (Early Breast Cancer (HR-positive, HER2-negative), Advanced or Metastatic Breast Cancer (HR-positive, HER2-negative), and Other Cancer Types (e.g., Lung Cancer, under research or off-label use)), By Dosage Strength (50 mg, 100 mg, 150 mg, and 200 mg), By Therapy Type (Monotherapy (Abemaciclib alone) and Combination Therapy (with endocrine therapy, other cancer drugs)), By Line of Therapy (First-line endocrine-based treatment, Second-line after progression on prior endocrine therapy, and Third-line and later after chemotherapy), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), By End User (Academic oncology centers, Comprehensive cancer hospitals, Private oncology clinics, Government/public hospitals, and Others (home care)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)